Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
University of Pennsylvania, Philadelphia.
JAMA Netw Open. 2024 Oct 1;7(10):e2441056. doi: 10.1001/jamanetworkopen.2024.41056.
Racial disparities in receipt of guideline-concordant care (GCC) among older patients with potentially curable breast cancer are understudied.
To determine whether rates of GCC, time to treatment initiation, and all-cause mortality in stage I to III breast cancer differ by race among older adults.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the National Cancer Database and included patients aged 65 years and older with stage I to III breast cancer, diagnosed between 2010 and 2019. Data analysis was conducted between July 2022 to July 2023.
Race, defined as non-Hispanic Black or non-Hispanic White.
The primary outcome was nonreceipt of GCC, defined using the National Comprehensive Cancer Network guidelines, and all-cause mortality. The secondary outcome was time to treatment initiation. Univariate and multivariate regression analysis were used to determine association between exposure and outcomes. Models for GCC and all-cause mortality included age, stage, receptor status, year of diagnosis, Charlson-Deyo comorbidity index, insurance, health care setting, and neighborhood-level educational attainment and median income.
The analytic cohort included 258 531 participants (mean [SD] age, 72.5 [6.0] years), with 25 174 participants who identified as non-Hispanic Black (9.7%) and 233 357 participants who identified as non-Hispanic White (90.3%), diagnosed between 2010 and 2017. A total of 4563 non-Hispanic Black participants (18.1%) and 35 374 non-Hispanic White participants (15.2%) did not receive GCC. Non-Hispanic Black race, compared with non-Hispanic White race, was associated with increased odds of not receiving GCC in the multivariate analysis (adjusted odds ratio [aOR], 1.13; 95% CI, 1.08-1.17; P < .001). Non-Hispanic Black race was associated with 26.1% increased risk of all-cause mortality in the univariate analysis, which decreased to 4.7%, after adjusting for GCC and clinical and sociodemographic factors (adjusted hazard ratio, 1.05; 95% CI, 1.01-1.08; P = .006). Non-Hispanic White race, compared with non-Hispanic Black race, was associated with increased odds of initiating treatment within 30 (OR, 1.65; 95% CI, 1.6-1.69), 60 (OR, 2.11; 95% CI, 2.04-2.18), and 90 (OR, 2.39; 95% CI, 2.27-2.51) days of diagnosis.
In this cohort study, non-Hispanic Black race was associated with increased odds of not receiving GCC and less timely treatment initiation. Non-Hispanic Black race was associated with increased all-cause mortality, which was reduced after adjusting for GCC and clinical and sociodemographic factors. These findings suggest that optimizing timely receipt of GCC may represent a modifiable pathway to improving inferior survival outcomes among older non-Hispanic Black patients with breast cancer.
在有潜在治愈可能的老年乳腺癌患者中,接受指南一致的治疗(GCC)的种族差异研究较少。
确定在年龄较大的成年人中,种族是否会影响 I 期至 III 期乳腺癌的 GCC 率、治疗开始时间和全因死亡率。
设计、地点和参与者:本队列研究使用了国家癌症数据库的数据,包括年龄在 65 岁及以上、诊断为 I 期至 III 期乳腺癌的患者,诊断时间为 2010 年至 2019 年。数据分析于 2022 年 7 月至 2023 年 7 月进行。
种族,定义为非西班牙裔黑种人或非西班牙裔白种人。
主要结果是非接受 GCC,根据国家综合癌症网络指南定义,以及全因死亡率。次要结果是治疗开始时间。使用单变量和多变量回归分析来确定暴露与结果之间的关联。用于 GCC 和全因死亡率的模型包括年龄、阶段、受体状态、诊断年份、Charlson-Deyo 合并症指数、保险、医疗保健环境以及邻里级别的教育程度和中位数收入。
分析队列包括 258531 名参与者(平均[标准差]年龄,72.5[6.0]岁),其中 25174 名参与者是非西班牙裔黑人(9.7%),233357 名参与者是非西班牙裔白人(90.3%),诊断时间为 2010 年至 2017 年。共有 4563 名非西班牙裔黑人参与者(18.1%)和 35374 名非西班牙裔白人参与者(15.2%)未接受 GCC。在多变量分析中,与非西班牙裔白人种族相比,非西班牙裔黑人种族与不接受 GCC 的可能性更高相关(调整后的优势比[OR],1.13;95%置信区间[CI],1.08-1.17;P<0.001)。非西班牙裔黑人种族与全因死亡率增加 26.1%相关,在调整了 GCC 和临床及社会人口学因素后,这一比例下降至 4.7%(调整后的危害比[HR],1.05;95%CI,1.01-1.08;P=0.006)。与非西班牙裔黑人种族相比,非西班牙裔白种人种族与在 30 天(OR,1.65;95%CI,1.6-1.69)、60 天(OR,2.11;95%CI,2.04-2.18)和 90 天(OR,2.39;95%CI,2.27-2.51)内开始治疗的可能性更高相关。
在这项队列研究中,非西班牙裔黑人种族与不接受 GCC 和治疗开始时间延迟的可能性更高相关。非西班牙裔黑人种族与全因死亡率增加相关,在调整了 GCC 和临床及社会人口学因素后,这一比例降低。这些发现表明,优化及时接受 GCC 可能是改善非西班牙裔黑人老年乳腺癌患者生存结局的一个可改变的途径。